摘要
肝癌是常见的恶性肿瘤之一,恶性程度高、死亡率高,其早期诊断对于病人的治疗极为重要。目前临床广为使用的甲胎蛋白检测与影像学相结合的方式,在早期肝癌的敏感性和特异性诊断方面尚存在一些缺陷,寻找更有效的新肿瘤标志物是临床期盼的需求。高尔基体糖蛋白73(Golgi protein-73,GP73)是存在于高尔基体的一种II型跨膜糖蛋白,在早期肝癌患者血清内表达上调,近年来有很多研究认为GP73是最有潜力的肝癌血清标志物之一。本文就近年来GP73与肝癌关系的研究进展做综述。
Hepatocellular carcinoma（HCC） is one of the global prevalence malignant tumors with high malignant level and mortality.Accurate diagnosis of HCC in early stage allows physicians to provide patients the best possible therapeutic options.Alpha-fetoprotein（AFP） combined with ultrasonography are current standards of clinical practice for at-risk patients.However,the sensitivity and specifcity of both AFP levels and ultrasonography for HCC surveillance have some shortcomings,particularly in the early stages of HCC.Finding more effective new tumor markers of hepatocellular remains highly unmet need.Golgi protein-73（GP73） is a type II Golgi-localized integral membrane protein that normally expressed in epithelial cells of many human tissues.It is up-regulated in serum samples from patients with HCC.And recently there are many reports about serum GP73 as one of the most promising serum markers for the diagnosis of HCC.This report provides a systematic review about the relationship between GP73 and HCC.
出处
《分子诊断与治疗杂志》
2013年第5期339-346,共8页
Journal of Molecular Diagnostics and Therapy
基金
十二五国家高技术研究发展计划(863计划)(2012AA020205)
关键词
肝癌
诊断
GP73
进展
Hepatocellular carcinoma
Diagnosis
Golgi protein-73
Progress
